Volume 22 - Issue 10 - October 2009
Diabetes Watch »
Diabetic foot osteomyelitis continues to be one of the more challenging entities to diagnose and treat accurately. Although there are established clinical practice guidelines set forth by the Infectious Diseases Society of America (IDSA), deviations from these guidelines often exist from one treatment facility to the next.1
News and Trends »
New Federal Rules Address Patient Record Breaches
By Brian McCurdy, Senior Editor
Podiatry practices already spend a great deal of administrative time complying with the rules of the Health Insurance Portability and Accountability Act (HIPAA). However, practices will now need to adjust to new patient privacy provisions that ensure no personal health records are breached.
When complications occur following subtalar joint fusion, surgeons may need to weigh revisional surgery options in order to correct the deformity. This author discusses common indications for revisional arthrodesis and offers step-by-step pearls to help ensure optimal outcomes.
Given the common prevalence and debilitating effects of neuropathic pain, it is important to have a strong understanding of effective treatment options. Accordingly, this author reviews the literature on currently available modalities as well as emerging therapies.
Given the complexities of the second crossover toe deformity, these authors discuss key pathomechanics, review essential elements to the clinical examination, offer conservative care options and provide insights on different surgical techniques.
The crossover second toe deformity may be one of the most challenging surgical disorders foot and ankle surgeons face. The condition is most often associated with a pronounced hallux valgus deformity that one must address surgically in order to achieve a satisfactory and lasting result.
Given the significant prevalence of onychomycosis that podiatrists see in practice, these authors review current treatments and offer a closer look at emerging topicals, orals and devices that may hold promise in treating this disease.
Since the drug companies’ fungal wars of the 1990s, many podiatrists have lost interest in the treatment of onychomycosis and have settled into their own particular treatment paradigm. However, emerging technologies and new drug delivery systems have again brought the treatment of onychomycosis to the forefront of our profession.